Positive News SentimentPositive NewsNASDAQ:BCTX BriaCell Therapeutics (BCTX) Stock Price, News & Analysis $0.79 -0.02 (-2.46%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About BriaCell Therapeutics Stock (NASDAQ:BCTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's Range$0.78▼$0.8350-Day Range$0.47▼$1.2452-Week Range$0.46▼$5.97Volume332,317 shsAverage Volume1.63 million shsMarket Capitalization$28.47 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewBriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More… Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… BriaCell Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks59th Percentile Overall ScoreBCTX MarketRank™: BriaCell Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 475th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about BriaCell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BriaCell Therapeutics are expected to grow in the coming year, from ($0.58) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BriaCell Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.30% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BriaCell Therapeutics has recently increased by 61.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.30% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BriaCell Therapeutics has recently increased by 61.98%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentBriaCell Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BriaCell Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for BCTX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.77% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.42% of the stock of BriaCell Therapeutics is held by institutions.Read more about BriaCell Therapeutics' insider trading history. Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCTX Stock News HeadlinesBriaCell announces survival data from Phase 2 metastatic breast cancer studyOctober 22, 2024 | markets.businessinsider.comBriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22, 2024 | globenewswire.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonNovember 2, 2024 | Porter & Company (Ad)BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal StudyOctober 15, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5 Million OfferingOctober 2, 2024 | globenewswire.comBriaCell Therapeutics Announces $5 Million OfferingOctober 1, 2024 | globenewswire.comBriaCell dips despite promising mid-stage data for breast cancer therapyOctober 1, 2024 | seekingalpha.comBriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” TumorOctober 1, 2024 | globenewswire.comSee More Headlines BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? BriaCell Therapeutics' stock was trading at $5.85 at the beginning of the year. Since then, BCTX stock has decreased by 86.4% and is now trading at $0.7945. View the best growth stocks for 2024 here. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (NASDAQ:BCTX) posted its earnings results on Monday, October, 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.45. When did BriaCell Therapeutics IPO? BriaCell Therapeutics (BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. Who are BriaCell Therapeutics' major shareholders? BriaCell Therapeutics' top institutional investors include Vontobel Holding Ltd. (0.44%). View institutional ownership trends. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BriaCell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Plug Power (PLUG), Micron Technology (MU) and Permian Basin Royalty Trust (PBT). Company Calendar Last Earnings10/28/2024Today11/02/2024Next Earnings (Estimated)12/12/2024Fiscal Year End7/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+1,788.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-44.65% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-3.31Miscellaneous Outstanding Shares35,840,000Free Float28,036,000Market Cap$28.47 million OptionableOptionable Beta1.34 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:BCTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.